Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management

Journal of the American Academy of Dermatology

Volumn 67, Issue 6, 2012, Pages 1349-1361

  Abramson, Amanda ^a   Menter, Alan ^a   Perrillo, Robert ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chronic hepatitis B; hepatitis B virus; liver function tests; psoriasis; tumor necrosis factor alpha inhibitor

Indexed keywords

ADALIMUMAB; ADEFOVIR; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; RITUXIMAB; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIVIRAL THERAPY; DRUG CONTRAINDICATION; GENOMICS; HEPATITIS B; HUMAN; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR; SENESCENCE; VIRUS REACTIVATION;

DRUG-INDUCED LIVER INJURY; HEPATITIS B, CHRONIC; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869105739     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.04.036     Document Type: Review

References (119)

1. S.-J. Chung, J.K. Kim, M.-C. Park, Y.-B. Park, and S.-K. Lee Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-α therapy J Rheumatol 36 2009 2416 2420
2. M.F. Sorrell, E.A. Belongia, J. Costa, I.F. Gareen, J.L. Grem, and J.M. Inadomi National Institutes of Health consensus development conference statement: management of hepatitis B Hepatology 49 2009 S4 12
3. W.M. Lee Hepatitis B virus infection N Engl J Med 337 1997 1733 1745
4. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
5. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850
6. J.D. Bahner, L.Y. Cao, and N.J. Korman Biologics in the management of psoriasis Clin Cosmet Investig Dermatol 2 2009 111 128
7. Y.W. Yang, J.J. Keller, and H.C. Lin Medical comorbidity associated with psoriasis in adults: a population-based study Br J Dermatol 165 2011 1037 1043
8. M.J. Shale, C.H. Seow, C.S. Coffin, G.G. Kaplan, R. Panaccione, and S. Ghosh Review article: chronic viral infection in the anti-tumor necrosis factor therapy era in inflammatory bowel disease Aliment Pharmacol Ther 31 2010 20 34
9. C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, and D.A. Chandler British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009 Br J Dermatol 161 2009 987 1019
10. J.T. Giles, and J.M. Bathon Serious infections associated with anticytokine therapies in the rheumatic diseases J Intensive Care Med 19 2004 320 334
11. M.B. Carroll, and M.I. Bond Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection Semin Arthritis Rheum 38 2008 208 217
12. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 2001 907 916
13. S.L. Gottlieb, P. Gilleaudeau, R. Johnson, L. Estes, T.G. Woodworth, and A.B. Gottlieb Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis Nat Med 1 1995 442 447
14. H. Nishimura, M. Emoto, K. Hiromatsu, S. Yamamoto, K. Matsuura, and H. Gomi The role of gamma delta T cells in priming macrophages to produce tumor necrosis factor-alpha Eur J Immunol 25 1995 1465 1468
15. P.J. Barnes, and M. Karin Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N Engl J Med 336 1997 1066 1071
16. A.B. Gottlieb, A.D. Luster, D.N. Posnett, and D.M. Carter Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques J Exp Med 168 1988 941 948
17. T. Gomi, T. Shiohara, T. Munakata, K. Imanishi, and M. Nagashima Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis Arch Dermatol 127 1991 827 830
18. B.J. Nickoloff, G.D. Karabin, J.N. Barker, C.E. Griffiths, V. Sarma, and R.S. Mitra Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis Am J Pathol 138 1991 129 140
19. R. Caporali, F. Bobbio-Pallavicini, F. Atzeni, G. Sakellariou, M. Caprioli, and C. Montecucco Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases Arthritis Care Res 62 2010 749 754
20. F. Prignano, F. Ricceri, L. Pescitelli, F. Zanieri, and T. Lotti Tumor necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients Br J Dermatol 164 2011 645 647
21. G. Herbein, and W.A. O'Brien Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis Proc Soc Exp Biol Med 223 2000 241 257
22. L.G. Guidotti, and F.V. Chisari Noncytolytic control of viral infections by the innate and adaptive immune response Annu Rev Immunol 19 2001 65 91
23. J.F. Schlaak, G. Tully, H.F. Löhr, and G. Gerken Meyer zum Büschenfelde KH. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines Clin Exp Immunol 115 1999 508 514
24. T.F. Baumert, R. Thimme, and F. von Weizsacker Pathogenesis of hepatitis B virus infection World J Gastroenterol 13 2007 82 90
25. M.J. Hussain, J.Y. Lau, R. Williams, and D. Vergani Hepatic expression of tumor necrosis factor-alpha in chronic hepatitis B virus infection J Clin Pathol 47 1994 1112 1115
26. H.M. Daniels, A. Meager, A.L. Eddleston, G.J. Alexander, and R. Williams Spontaneous production of tumor necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection Lancet 335 1990 875 877
27. M. Carroll, and M. Forgione Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action Clin Rheumatol 29 2010 1021 1029
28. C. Fotiadou, E. Lazaridou, and D. Ioannides Safety of anti-tumor necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature J Eur Acad Dermatol Venereol 25 2011 471 474
29. S. Zingarelli, M. Frassi, C. Bazzani, M. Scarsi, M. Puoti, and P. Airo Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature J Rheumatol 36 2009 1188 1194
30. T. Banno, A. Gazel, and M. Blumenberg Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling J Biol Chem 279 2004 32633 32642
31. T. Banno, M. Adachi, L. Mukkamala, and M. Blumenberg Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling Antivir Ther 8 2003 541 554
32. L.G. Guidotti, T. Ishikawa, M.V. Hobbs, B. Matzke, R. Schreiber, and F.V. Chisari Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes Immunity 4 1996 25 36
33. N. Sheron, J.Y. Lau, H.M. Daniels, J. Webster, A.L. Eddleston, and G.J. Alexander Tumor necrosis factor to treat chronic hepatitis B virus infection Lancet 336 1990 321 322
34. M. Ramos-Casals Therapy: are TNF blockers safe for patients with hepatitis B virus infection? Nat Rev Rheumatol 6 2010 618 620
35. B. Rehermann Intrahepatic T cells in hepatitis B: viral control versus liver cell injury J Exp Med 191 2000 1263 1268
36. S. Ocana, M.L. Casas, I. Buhigas, and J.L. Lledo Diagnostic strategy for occult hepatitis B virus infection World J Gastroenterol 17 2011 1553 1557
37. R.P. Perrillo Hepatitis B and D M. Feldman, L. Friedman, L. Brandt, Sleisinger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis and management 2010 Saunders, Elsevier Philadelphia 1287 1312
38. B. Roche, and D. Samuel The difficulties of managing severe hepatitis B virus reactivation Liver Int 31 Suppl 2011 104 110
39. W. Ohishi, and K. Chayama Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy Clin Exp Nephrol 15 2011 634 640
40. R.A. de la Fuente, M.L. Gutierrez, J. Garcia-Samaniego, C. Fernandez-Rodriguez, J.L. Lledo, and G. Castellano Pathogenesis of occult chronic hepatitis B virus infection World J Gastroenterol 17 2011 1543 1548
41. J.L. Lledo, C. Fernandez, M.L. Gutierrez, and S. Ocana Management of occult hepatitis B virus infection: an update for the clinician World J Gastroenterol 17 2011 1563 1568
42. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, and G. Lau Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 2004 1750 1758
43. A.S. Lok, R.H. Liang, E.K. Chiu, K.L. Wong, T.K. Chan, and D. Todd Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study Gastroenterology 100 1991 182 188
44. W. Yeo, P.K. Chan, H.L. Chan, F.K. Mo, and P.J. Johnson Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis J Med Virol 65 2001 473 477
45. L.H. Calabrese, N.N. Zein, and D. Vassilopoulos Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 2006 983 989
46. A. Berger, W. Preiser, H.G. Kachel, M. Stürmer, and H.W. Doerr HBV reactivation after kidney transplantation J Clin Virol 32 2005 162 165
47. C. Charpin, S. Guis, P. Colson, P. Borentain, J.-P. Mattéi, and P. Alcaraz Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients Arthritis Res Ther 11 2009 1 5
48. J.S. Lubel, and P.W. Angus Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management J Gastroenterol Hepatol 25 2010 864 871
49. J.S. Lubel, A.G. Testro, and P.W. Angus Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management Intern Med J 37 2007 705 712
50. R.P. Perrillo Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease Gastroenterology 120 2001 1009 1022
51. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
52. Y.T. Cho, C.H. Chen, H.Y. Chiu, and T.F. Tsai Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan J Dermatol 39 2011 269 273
53. L.R. Braathen, G. Botten, and T. Bjerkedal Psoriatics in Norway: a questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption Acta Derm Venereol Suppl (Stockh) 142 1989 9 12
54. K. Poikolainen, T. Reunala, J. Karvonen, J. Lauharanta, and P. Kärkkäinen Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 300 1990 780 783
55. D.M. Sommer, S. Jenisch, M. Suchan, E. Christophers, and M. Weichenthal Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis Arch Dermatol Res 298 2006 321 328
56. W. Yeo, B. Zee, S. Zhong, P.K.S. Chan, W.L. Wong, and W.M. Ho Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy Br J Cancer 90 2004 1306 1311
57. M.L. Manzano-Alonso, and G. Castellano-Tortajada Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy World J Gastroenterol 17 2011 1531 1537
58. F. Fallahian, S.M. Alavian, V. Fallahian, and F. Zamani Impact of immunosuppression and chemotherapy on reactivation of viral hepatitis Saudi J Kidney Dis Transpl 21 2010 621 627
59. R. Loomba, A. Rowley, R. Wesley, T.J. Liang, J.H. Hoofnagle, and F. Pucino Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 2008 519 528
60. D. Vassilopoulos, A. Apostolopoulou, E. Hadziyannis, G.V. Papatheodoridis, S. Manolakopoulos, and J. Koskinas Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection Ann Rheum Dis 69 2010 1352 1355
61. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
62. R. de Franchis, A. Hadengue, G. Lau, D. Lavanchy, A. Lok, and N. McIntyre EASL international consensus conference on hepatitis B; 13-14 September, 2002, Geneva, Switzerland; consensus statement (long version) J Hepatol 39 Suppl 2003 S3 25
63. A. Marzano Management of HBV infection during immunosuppressive treatment Mediterr J Hematol Infect Dis 1 2009 e2009025
64. O.S. Khokhar, A. Farhadi, L. McGrail, and J.H. Lewis Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation Chemotherapy 55 2009 69 75
65. C.M. Weinbaum, I. Williams, E.E. Mast, S.A. Wang, L. Finelli, and A. Wasley Recommendations for identification and public health management of persons with chronic hepatitis B virus infection MMWR Recomm Rep 57 2008 1 20
66. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31e1 31e15
67. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
68. J. Sokolove, V. Strand, J.D. Greenberg, J.R. Curtis, A. Kavanaugh, and J.M. Kremer Risk of elevated liver enzymes associated with TNF inhibitor utilization in patients with rheumatoid arthritis Ann Rheum Dis 69 2010 1612 1617
69. D.M. Knight, H. Trinh, J. Le, S. Siegel, D. Shealy, and M. McDonough Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 30 1993 1443 1453
70. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial Lancet 357 2001 1842 1847
71. B.J. Scallon, M.A. Moore, H. Trinh, D.M. Knight, and J. Ghrayeb Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
72. A.B. Gottlieb, S. Masud, R. Ramamurthi, A. Abdulghani, P. Romano, and U. Chaudhari Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris J Am Acad Dermatol 48 2003 68 75
73. H.M. Lorenz, C. Antoni, T. Valerius, R. Repp, M. Grünke, and N. Schwerdtner In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects J Immunol 156 1996 1646 1653
74. I. Nestorov Clinical pharmacokinetics of tumor necrosis factor antagonists J Rheumatol Suppl 74 2005 13 18
75. I. Nestorov Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34 2005 12 18
76. M. Esteve, C. Saro, F. González-Huix, F. Suarez, M. Forné, and J.M. Viver Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis Gut 53 2004 1363 1365
77. J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, and W. Kirch Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials Br J Dermatol 159 2008 513 526
78. A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, and A. Menter Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Br J Dermatol 159 2008 274 285
79. J.R. Wands, C.M. Chura, F.J. Roll, and W.C. Maddrey Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders Gastroenterology 68 1975 105 112
80. R.M. Galbraith, A.L. Eddleston, R. Williams, and A.J. Zuckerman Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy Lancet 2 1975 528 530
81. K.B. Gordon, R.G. Langley, C. Leonardi, D. Toth, M.A. Menter, and S. Kang Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 55 2006 598 606
82. M.H. Weisman, L.W. Moreland, D.E. Furst, M.E. Weinblatt, E.C. Keystone, and H.E. Paulus Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study Clin Ther 25 2003 1700 1721
83. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115
84. G.M. Bartelds, C.L. Krieckaert, M.T. Nurmohamed, P.A. van Schouwenburg, W.F. Lems, and J.W. Twisk Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up JAMA 305 2011 1460 1468
85. V. Strand, R. Kimberly, and J.D. Isaacs Biologic therapies in rheumatology: lessons learned, future directions Nat Rev Drug Discov 6 2007 75 92
86. H. Zhou Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein J Clin Pharmacol 45 2005 490 497
87. I. Nestorov, R. Zitnik, T. DeVries, A.M. Nakanishi, A. Wang, and C. Banfield Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis Br J Clin Pharmacol 62 2006 435 445
88. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.Y. Song, and D. Shealy Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426
89. C. Keller, A. Webb, and J. Davis Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review Ann Rheum Dis 62 2003 1128 1132
90. J.M. Korth-Bradley, A.S. Rubin, R.K. Hanna, D.K. Simcoe, and M.E. Lebsack The pharmacokinetics of etanercept in healthy volunteers Ann Pharmacother 34 2000 161 164
91. R. Mössner, M.P. Schön, and K. Reich Tumor necrosis factor antagonists in the therapy of psoriasis Clin Dermatol 26 2008 486 502
92. A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
93. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
94. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial Lancet 366 2005 1367 1374
95. M.H. Núñez-Rodríguez, A. Santamaría- Martínez, L. Mata-Román, and A. Caro-Patón Reactivation of hepatitis B treated with adefovir after infliximab administration [in Spanish] Med Clin (Barc) 126 2006 558 559
96. A. Conde-Taboada, J.P. Munoz, L.C. Munoz, and E. Lopez-Bran Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection J Am Acad Dermatol 60 2009 1077 1080
97. T. Kaiser, J. Moessner, K. Patel, J.G. McHutchison, and H.L. Tillmann Life threatening liver disease during treatment with monoclonal antibodies BMJ 338 2009 b508
98. L. Nosotti, F. Francesconi, S. Izzi, E. Berardesca, A. Morrone, and C. Bonifati Safety of antitumor necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection Br J Dermatol 162 2010 1408 1410
99. M. Kouba, S.E. Rudolph, P. Hrdlicka, and M.A. Zuber Hepatitis-B reactivation during treatment with tumor necrosis factor-α blocker adalimumab in a patient with psoriasis arthritis [in German] Dtsch Med Wochenschr 137 2012 23 26
100. G.V. Papatheodoridis, E.K. Manesis, S. Manolakopoulos, I.S. Elefsiniotis, J. Goulis, and J. Giannousis Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 48 2008 1451 1459
101. N. Cassano, V. Mastrandrea, M. Principi, F. Loconsole, N. De Tullio, and A. Di Leo Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease J Biol Regul Homeost Agents 25 2011 285 289
102. R. Pérez-Alvarez, C. Díaz-Lagares, F. García- Hernández, L. Lopez-Roses, P. Brito-Zerón, and M. Pérez-de-Lis Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases Medicine (Baltimore) 90 2011 359 371
103. C. Loras, J.P. Gisbert, M. Mínguez, O. Merino, L. Bujanda, and C. Saro Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy Gut 59 2010 1340 1346
104. J.H. Hoofnagle Reactivation of hepatitis B Hepatology 49 2009 S156 S165
105. W. Yeo, P.K. Chan, W.M. Ho, B. Zee, K.C. Lam, and K.I. Lei Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy J Clin Oncol 22 2004 927 934
106. C. Hsu, C.A. Hsiung, I.J. Su, W.S. Hwang, M.C. Wang, and S.F. Lin A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial Hepatology 47 2008 844 853
107. T. Cil, A. Altintas, S. Pasa, K. Bayan, T. Ozekinci, and A. Isikdogan Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy Leuk Lymphoma 49 2008 939 947
108. M.S. Dai, P.F. Wu, R.Y. Shyu, J.J. Lu, and T.Y. Chao Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration Liver Int 24 2004 540 546
109. G.K. Lau, A. Lie, and R. Liang Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy Blood 100 2002 3054
110. G. Rossi, A. Pelizzari, M. Motta, and M. Puoti Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy Br J Haematol 115 2001 58 62
111. A. Ahmed, and E.B. Keeffe Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection Am J Gastroenterol 94 1999 249 251
112. W. Yeo, W.M. Ho, P. Hui, P.K. Chan, K.C. Lam, and J.J. Lee Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients Breast Cancer Res Treat 88 2004 209 215
113. N.D. Simpson, P.W. Simpson, A.M. Ahmed, M.H. Nguyen, G. Garcia, and E.B. Keeffe Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine J Clin Gastroenterol 37 2003 68 71
114. L.L. Lim, C.T. Wai, Y.M. Lee, H.L. Kong, R. Lim, and E. Koay Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients Aliment Pharmacol Ther 16 2002 1939 1944
115. T. Vassiliadis, V. Garipidou, K. Tziomalos, V. Perifanis, O. Giouleme, and S. Vakalopoulou Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy-a prospective case series Am J Hematol 80 2005 197 203
116. L.A. Martyak, E. Taqavi, and S. Saab Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis Liver Int 28 2008 28 38
117. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol doi: 10.1007/s10067-010-1438-y. Published online April 9, 2010.
118. C. Colbert, A. Chavarria, and C. Berkelhammer Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease Inflamm Bowel Dis 13 2007 1453 1454
119. G.M. McQuillan, T.R. Townsend, C.B. Johannes, T. Dillard, R.A. Molteni, and P.M. Ness Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population Am J Epidemiol 126 1987 484 491